Excellus (#2.02.60) Germline Genetic Testing for Hereditary Cancers//New Policy

This new medical policy was created to combine the criteria from corporate medical policies #2.02.06 Genetic Testing for Hereditary BRCA Mutations, #2.02.07 Genetic Testing for Germline Mutations of the RET Proto Oncogene in Medullary Carcinoma of the Thyroid, #2.02.11 Genetic Testing for Inherited Susceptibility to Colorectal Cancer, and #2.02.44 Genetic Testing for Susceptibility to Hereditary Cancers.